Dik J. Kwekkeboom

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Massimo Falconi, Barbro Eriksson, Gregory Kaltsas et al. · Neuroendocrinology · 2016 · 1.4K citations · Full text

Medicine, Endocrinology, Oncology +17

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 809 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

Medicine, Oncology, Pharmacology +15